Charles Schwab’s Definium Therapeutics DFTX Stock Holding History
Bought
Maintained
Sold
Other funds holding DFTX
DCM
ACA
DTC
OCA
CC
Charles Schwab's DFTX Position: Q1 2026 in Review
Charles Schwab increased its Definium Therapeutics (DFTX) stake by 0.18% in Q1 2026, buying an estimated $24.9K and bringing the position to 808,715 shares worth $15.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1891.
Charles Schwab first reported a position in DFTX in Q2 2021 and has held it in 18 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.
- Charles Schwab held 808,715 shares of Definium Therapeutics worth $15.3M as of Q1 2026.
- Charles Schwab bought 1,466 Definium Therapeutics shares in Q1 2026, an estimated $24.9K.
- Definium Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #1891 holding.
- Charles Schwab first reported a position in Definium Therapeutics in Q2 2021 and has held it in 18 quarters since.
- 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.